Related Experiment Video
Updated: Aug 13, 2026
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Gene expression profiling and outcome prediction in non-Hodgkin lymphoma
1daves@mail.nih.gov
Abstract:
Gene expression profiling with microarrays has provided new insights into the molecular biology of tumors can that underlie differences in responses to therapy and patient outcomes. In diffuse large B-cell lymphoma, gene expression profiling has revealed at least 2 diseases that are strikingly different in their response to chemotherapy and the inhibition of critical oncogenic pathways. In follicular lymphoma, gene expression profiling showed that the host immune response to tumors is an important determinant of outcome and can strongly predict survival at the time of diagnosis. The application of immunologic therapies that modify the host immune response could have a major effect on survival in patients with follicular lymphoma. Thus, the application of gene expression profiling in non-Hodgkin lymphoma provides important prognostic information at the time of diagnosis and can be translated into therapeutic options that improve patient outcomes.
Insights
Gene expression profiling reveals distinct subtypes of diffuse large B-cell lymphoma and identifies immune response as a key survival predictor in follicular lymphoma, guiding targeted therapies.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Gene expression profiling using microarrays offers insights into tumor biology, influencing therapy response and patient outcomes.
- Distinct molecular subtypes within non-Hodgkin lymphoma (NHL) impact treatment efficacy and prognosis.
Purpose of the Study:
- To investigate the utility of gene expression profiling in understanding non-Hodgkin lymphoma subtypes.
- To identify prognostic markers and therapeutic targets in diffuse large B-cell lymphoma and follicular lymphoma.
Main Methods:
- Microarray-based gene expression profiling was employed.
- Analysis focused on identifying distinct molecular signatures in lymphoma subtypes.
- Correlation of gene expression patterns with clinical outcomes and therapeutic responses was performed.
Main Results:
- Gene expression profiling identified at least two distinct diseases within diffuse large B-cell lymphoma with differing responses to chemotherapy and oncogenic pathway inhibition.
- In follicular lymphoma, the host immune response signature strongly predicted patient survival at diagnosis.
- Prognostic information derived from gene expression profiling can be translated into therapeutic strategies.
Conclusions:
- Gene expression profiling provides critical prognostic information for non-Hodgkin lymphoma at diagnosis.
- Understanding molecular subtypes and host immune responses can guide the development of targeted immunologic therapies.
- Application of gene expression profiling can lead to improved patient outcomes in non-Hodgkin lymphoma.
